Industry News
Biotechnology Industry News
After oncology wind-down, TG’s pivot to MS faces setback as FDA pushes approval decision
After oncology wind-down, TG's pivot to MS faces setback as FDA pushes approval decision jwaldron Tue, 05/31/2022 - 08:53
Bouncing back from late-phase fail, Minoryx pockets €51M to guide rare disease drug to market
Bouncing back from late-phase fail, Minoryx pockets €51M to guide rare disease drug to market ntaylor Tue, 05/31/2022 - 08:22
GSK strikes $3.3B Affinivax buyout to MAP out challenge to Pfizer’s blockbuster pneumococcal vaccine
GSK strikes $3.3B Affinivax buyout to MAP out challenge to Pfizer's blockbuster pneumococcal vaccine ntaylor Tue, 05/31/2022 - 05:20
RhoVac’s prostate cancer vaccine phase 2 failure forces biotech to cut costs
RhoVac's prostate cancer vaccine phase 2 failure forces biotech to cut costs jwaldron Mon, 05/30/2022 - 06:52
ASCO: Mirati cedes to Amgen’s Lumakras on durability in tight KRAS battle
ASCO: Mirati cedes to Amgen's Lumakras on durability in tight KRAS battle aarmstrong Fri, 05/27/2022 - 09:05
Addex’s eyelid data fail to make clear case for spasm expansion
Addex's eyelid data fail to make clear case for spasm expansion ntaylor Fri, 05/27/2022 - 07:43
Iovance sinks 50% as pivotal cell therapy data disappoint investors, but approval plan pushes ahead anyway
Iovance sinks 50% as pivotal cell therapy data disappoint investors, but approval plan pushes ahead anyway ntaylor Fri, 05/27/2022 - 04:57
ASCO: Genentech touts bispecific data for DLBCL, calling it ‘groundbreaking’ for heavily pretreated patients
ASCO: Genentech touts bispecific data for DLBCL, calling it 'groundbreaking' for heavily pretreated patients aarmstrong Thu, 05/26/2022 - 20:20
Chutes & Ladders—Alchemab CEO resigns immediately citing ‘personal reasons’
Chutes & Ladders—Alchemab CEO resigns immediately citing 'personal reasons' mbayer Thu, 05/26/2022 - 16:22
ASCO: Merck’s Keytruda combo data could spark hope for lymphoma patients who lack options
ASCO: Merck's Keytruda combo data could spark hope for lymphoma patients who lack options aarmstrong Thu, 05/26/2022 - 13:00
Avadel’s shares crumble as narcolepsy drug delayed yet again, this time on patent issue
Avadel's shares crumble as narcolepsy drug delayed yet again, this time on patent issue aarmstrong Thu, 05/26/2022 - 10:33
Vertex scoops up Catalyst’s complement pipeline for $60M cash
Vertex scoops up Catalyst’s complement pipeline for $60M cash mbayer Thu, 05/26/2022 - 09:47
With the right partner, Pfizer gains fast-track tag for previously shelved NASH drug
With the right partner, Pfizer gains fast-track tag for previously shelved NASH drug aarmstrong Thu, 05/26/2022 - 08:12
IN-ACTIV: NRx tanks as peptide fails NIH trial in severe COVID-19 patients
IN-ACTIV: NRx tanks as peptide fails NIH trial in severe COVID-19 patients ntaylor Thu, 05/26/2022 - 07:38
Biotech co-founder arrested on murder-for-hire charges
Biotech co-founder arrested on murder-for-hire charges ntaylor Thu, 05/26/2022 - 06:29
Flagship unveils ProFound Therapeutics with $75M to explore trove of new proteins
Flagship unveils ProFound Therapeutics with $75M to explore trove of new proteins mbayer Wed, 05/25/2022 - 17:03
Forte fields demand to liquidate from top shareholder who says latest asset came ‘out of thin air’
Forte fields demand to liquidate from top shareholder who says latest asset came 'out of thin air' mbayer Wed, 05/25/2022 - 11:02
BridgeBio’s CEO on staying alive, ‘motherhood and apple pie’
BridgeBio's CEO on staying alive, 'motherhood and apple pie' gmasson Wed, 05/25/2022 - 10:36
With failed COVID shot still dragging on earnings, CureVac tries to turn page to next-gen mRNA tech
With failed COVID shot still dragging on earnings, CureVac tries to turn page to next-gen mRNA tech aarmstrong Wed, 05/25/2022 - 09:45
Antios rocked as hepatitis B safety signal sparks clinical hold, termination of collaboration
Antios rocked as hepatitis B safety signal sparks clinical hold, termination of collaboration ntaylor Wed, 05/25/2022 - 07:43